The field of cancer treatment has long struggled with the immense costs and time-consuming nature of drug development.

AI-powered tools like Merck’s Aiddison can accelerate drug identification and optimise design, cutting both costs and time to ...

A new fully automated in vivo screening system (AISS) has been developed to transform drug evaluation by enabling rapid, ...

Artificial intelligence (AI) is emerging as a tool that can improve patient outcomes and provider care efficiency, says Douglas Flora, MD, FACCC, of St. Elizabeth Healthcare.

BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and increase success rates in drug development.

In essence, the future of AI is inextricably linked to advancements in data management, making it an indispensable enabler of ...

AI assistance was seen to speed screening and recruitment for clinical trials, potentially helping patients access novel therapies faster.

Modern AI technology is data-hungry. In many areas, data is scarce. For example, in our work in early oncology clinical trials, we only have data on about 20 patients, so we tend to use theory-based ...

Patients expressed concern that overreliance on artificial intelligence (AI) could lead to clinicians losing their skills, ...

Molecular Devices' CellXpress AI streamlines cell culture processes, reducing human error and improving efficiency in drug ...

Breast cancer patients who underwent postmastectomy breast reconstruction had lower sexual well-being scores compared with ...